重组凝血因子VIIa与安慰剂治疗症状发作2小时内自发性脑出血(FASTEST):一项多中心、双盲、随机、安慰剂对照3期试验
FASTEST是一项在93个中心开展的多中心、前瞻性、双盲、随机、安慰剂对照、适应性3期试验,纳入18-80岁、自发性脑出血2-60 mL、脑室内出血范围符合条件、GCS≥8、无近期缺血性卒中或心肌梗死、未使用抗凝药、症状发作或最后已知正常2小时内给药的患者,1:1随机接受80 μg/kg重组凝血因子VIIa或安慰剂静脉注射(2分钟内)。共筛查3288例,随机626例(安慰剂组298例,干预组328例),平均年龄61岁,平均给药时间100分钟。主要结局180天mRS在两组间无差异(校正共同OR 1.09,95%CI 0.79-1.51,p=0.61);4天内危及生命的血栓栓塞并发症干预组15例(<5%) vs 安慰剂组4例(1%),相对风险3.41(95%CI 1.14-10.15,p=0.020);重组凝血因子VIIa与血肿增长减少相关(-3.7 mL,95%CI -5.4至-1.9)及血肿加脑室内出血增长减少(-5.2 mL,-7.6至-2.8)。试验在第二次中期分析时达到预设无效停止标准。
要点
- 180天mRS在重组凝血因子VIIa组与安慰剂组间无差异:校正共同OR 1.09(95%CI 0.79-1.51),p=0.61。
- 4天内危及生命的血栓栓塞并发症:干预组15例(<5%) vs 安慰剂组4例(1%),相对风险3.41(95%CI 1.14-10.15),p=0.020。
- 重组凝血因子VIIa 80 μg/kg静脉注射(2分钟内)较安慰剂减少24小时血肿增长:-3.7 mL(95%CI -5.4至-1.9)。
- 重组凝血因子VIIa较安慰剂减少24小时血肿加脑室内出血增长:-5.2 mL(95%CI -7.6至-2.8)。
- 试验在第二次中期分析时达到预设无效停止标准,作者指出对继续出血风险最高患者的进一步测试正在进行中。
适用人群与场景
- 18-80岁成人,自发性脑出血2-60 mL,脑室内出血少于一个侧脑室的三分之二或少于双侧侧脑室的三分之一,GCS≥8分,无近期缺血性卒中或心肌梗死证据,未近期使用抗凝药物或其他结构性脑出血病因,且在症状发作或最后已知正常2小时内接受研究药物。
诊断标准与关键阈值
- 主要结局为180天功能结局,采用改良Rankin量表(mRS)评分0-2、3、4-6分评估。
- 主要安全结局为最初4天内危及生命的血栓栓塞事件。
- 次要目标为基线至给药后24小时CT扫描期间脑出血体积及脑出血加脑室内出血体积的变化。
处置流程与药物剂量
- 重组凝血因子VIIa 80 μg/kg,静脉注射,2分钟内给药,在症状发作或最后已知正常2小时内使用。
- 安慰剂为与重组凝血因子VIIa外观相同的制剂,同样静脉注射2分钟。
研究设计与关键结果
- 多中心、前瞻性、双盲、随机、安慰剂对照、适应性3期试验,93个中心,筛查3288例,随机626例(安慰剂组298例[48%],干预组328例[52%]),女性216例(35%),男性410例(65%),平均年龄61岁(SD 12),平均给药时间100分钟(SD 22)。
- 主要结局180天mRS在干预组与安慰剂组间无差异:校正共同OR 1.09(95%CI 0.79-1.51),p=0.61。
- 4天内危及生命的血栓栓塞并发症:干预组15例(<5%) vs 安慰剂组4例(1%),相对风险3.41(95%CI 1.14-10.15),p=0.020。
- 重组凝血因子VIIa较安慰剂减少基线至24小时CT脑出血增长:-3.7 mL(95%CI -5.4至-1.9)。
- 重组凝血因子VIIa较安慰剂减少基线至24小时CT脑出血加脑室内出血增长:-5.2 mL(95%CI -7.6至-2.8)。
- 试验在第二次中期分析时达到预设无效停止标准。
证据类型、等级与局限
- 证据类型:多中心、前瞻性、双盲、随机、安慰剂对照、适应性3期试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于自发性脑出血2小时内、符合FASTEST纳入标准的患者,重组凝血因子VIIa 80 μg/kg静脉注射虽可减缓血肿增长,但未改善180天功能结局,且危及生命的血栓栓塞并发症增加(干预组15例 vs 安慰剂组4例),作者结论认为其未改善功能结局并显示小幅增加的危及生命血栓栓塞并发症风险。
- 作者指出对继续出血风险最高患者的重组凝血因子VIIa进一步测试正在进行中。
指南或共识出处
- FASTEST试验,ClinicalTrials.gov注册号NCT03496883。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Recombinant factor VIIa has been shown to slow bleeding in patients with intracerebral haemorrhage (ICH), but no haemostatic agent has been shown to improve clinical outcomes. We aimed to evaluate the safety, clinical efficacy, and effect on growth of ICH and intraventricular haemorrhage (IVH) of recombinant factor VIIa in patients with acute spontaneous ICH who were most likely to benefit from treatment with this agent.
METHODS: We conducted a multicentre, prospective, double-blind, randomised, placebo-controlled, adaptive, phase 3 trial (FASTEST) at 93 sites across the USA, Japan, Canada, Spain, Germany, and the UK. Adults aged 18-80 years with a spontaneous ICH of 2-60 mL, IVH in less than two-thirds of one lateral ventricle or in less than a third of both lateral ventricles, a Glasgow Coma Scale score of at least 8, no evidence of recent ischaemic stroke or myocardial infarction, no recent use of anticoagulation medication or other structural cause of ICH, and who had been treated with study medication within 2 h of stroke onset or last known well were eligible for inclusion. Patients were randomly assigned (1:1) by a simple randomisation scheme to either 80 μg/kg recombinant factor VIIa (intervention group) or an identical placebo (placebo group), administered intravenously over 2 min. All investigators and participants were masked to allocated group assignment. The primary outcome was functional outcome at 180 days, measured by modified Rankin Scale (mRS; score 0-2, 3, and 4-6) and analysed by intention to treat in all randomly assigned patients. The primary safety outcome was life-threatening thromboembolic events during the first 4 days, assessed in all randomly assigned participants. The secondary aim was change in ICH volume and ICH plus IVH volume between baseline and 24 h of treatment administration. We performed an ordinal logistic regression, adjusted for age, baseline ICH volume, baseline IVH volume, and pre-stroke mRS. Preplanned interim analyses, including adaptive sample size re-estimation and enrichment to a younger subgroup (aged ≤70 years), were also conducted. This trial is registered with ClinicalTrials.gov (NCT03496883) and is closed to new participants.
FINDINGS: Between Dec 3, 2021, and Oct 1, 2025, we screened 3288 patients, of whom 626 participants were randomly assigned and included in the intention-to-treat analyses: 298 (48%) in the placebo group and 328 (52%) in the intervention group. 216 (35%) participants were female and 410 (65%) were male, with a mean age of 61 years (SD 12). Mean time from stroke onset to administration of study drug was 100 min (SD 22). The trial met the prespecified stopping criteria for futility at the second interim analysis. There was no differential effect in the primary clinical outcome measure of mRS at 180 days between the intervention group and placebo group (adjusted common odds ratio 1·09 [95% CI 0·79-1·51]; p=0·61). Life-threatening thromboembolic complications within 4 days occurred in 15 (<5%) participants in the intervention group and in four (1%) in the placebo group (relative risk 3·41 [95% CI 1·14-10·15]; p=0·020). Compared with placebo, recombinant factor VIIa was associated with decreased growth of ICH (-3·7 mL [95% CI -5·4 to -1·9]) and of ICH plus IVH growth (-5·2 mL [-7·6 to -2·8]) between baseline and CT scan at 24 h.
INTERPRETATION: Recombinant factor VIIa administered within 2 h of ICH onset slowed haematoma growth, but did not improve functional outcomes and showed a small increased risk of life-threatening thromboembolic complications. Further testing of recombinant factor VIIa in patients with the greatest risk of continued bleeding is ongoing.
FUNDING: National Institute of Neurological Diseases and Stroke, Japan Agency for Medical Research and Development, and Novo Nordisk.
参考来源
- Broderick JP, Naidech AM, Elm JJ, et al. Recombinant factor VIIa versus placebo for spontaneous intracerebral haemorrhage within 2 h of symptom onset (FASTEST): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2026. PMID: 41653933. doi:10.1016/S0140-6736(26)00097-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。